Table 5.

CMV-specific immune reconstitution and outcome of CMV reactivation/disease in 25 patients who received CMV-specific T-cell therapy


Patient no.

Cell therapy, day after transplantation

CMV specific CD4+ reconstitution, day after cell therapy

CMV-specific CD8+ reconstitution, day after cell therapy

pp65 antigenemia after cell therapy*

CMV disease (onset after transplantation, wk)

Outcome (time after diagnosis, wk)
1   16   21   21   —   —   —  
2   23   21   21   —   —   —  
3   14   21   21   —   —   —  
4   21   21   21   —   —   —  
5   13   21   21   10   IP/CNS (2)   Resolution (3)  
6   32   21   21   —   —   —  
7   37   21   21   7 ± 6   CNS (12)   Death (4)  
8   16   21   21   13 ± 7   Enteritis (15)   Death (2)  
9   37   21   21   —   —   —  
10   26   21   21   —   —   —  
11   15   21   21   —   —   —  
12   22   21   21   —   —   —  
13   21   21   21   —   IP (3)   Resolution (4)  
14   21   21   21   4 ± 1   —   —  
15   17   21   21   —   —   —  
16   21   21   21   10   —   —  
17   33   21   21   —   —   —  
18   26   21   21   —   —   —  
19   16   21   21   7 ± 3   —   —  
20   28   21   21   —   CNS (5)   Resolution (5)  
21   17   21   21   —   —   —  
22   37   21   21   10   —   —  
23   27   21   21   —   —   —  
24   28   21   21   —   —   —  
25
 
21
 
21
 
21
 

 

 

 

Patient no.

Cell therapy, day after transplantation

CMV specific CD4+ reconstitution, day after cell therapy

CMV-specific CD8+ reconstitution, day after cell therapy

pp65 antigenemia after cell therapy*

CMV disease (onset after transplantation, wk)

Outcome (time after diagnosis, wk)
1   16   21   21   —   —   —  
2   23   21   21   —   —   —  
3   14   21   21   —   —   —  
4   21   21   21   —   —   —  
5   13   21   21   10   IP/CNS (2)   Resolution (3)  
6   32   21   21   —   —   —  
7   37   21   21   7 ± 6   CNS (12)   Death (4)  
8   16   21   21   13 ± 7   Enteritis (15)   Death (2)  
9   37   21   21   —   —   —  
10   26   21   21   —   —   —  
11   15   21   21   —   —   —  
12   22   21   21   —   —   —  
13   21   21   21   —   IP (3)   Resolution (4)  
14   21   21   21   4 ± 1   —   —  
15   17   21   21   —   —   —  
16   21   21   21   10   —   —  
17   33   21   21   —   —   —  
18   26   21   21   —   —   —  
19   16   21   21   7 ± 3   —   —  
20   28   21   21   —   CNS (5)   Resolution (5)  
21   17   21   21   —   —   —  
22   37   21   21   10   —   —  
23   27   21   21   —   —   —  
24   28   21   21   —   —   —  
25
 
21
 
21
 
21
 

 

 

 

— indicates no manifestations of CMV disease and negative antigenemia; IP, interstitial pneumonia; CNS, brain lesion.

*

Positive antigenemias (no. of positive cells/200 000 cells) detected weekly from 3 to 12 weeks after T-cell therapy. Single number indicates 1 episode of reactivation. Two numbers indicate 2 episodes of reactivation. Mean ± SD indicates 3 or more episodes of reactivation

Close Modal

or Create an Account

Close Modal
Close Modal